Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005576 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
A Phase 1 study of Recurrent Neuroblastoma and Regional Neuroblastoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT00005576 is a Phase 1 study of Recurrent Neuroblastoma and Regional Neuroblastoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 6 participants, below the 1,139-participant average among 9 other Recurrent Neuroblastoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00005576, a Phase 1 study of Recurrent Neuroblastoma and Regional Neuroblastoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining monoclonal antibody therapy with sargramostim or interleukin-2 may kill more tumor cells. Phase I trial to study the effectiveness of monoclonal antibody therapy given with sargramostim and interleukin-2 in treating children with neuroblastoma who have just completed bone marrow or peripheral stem cell transplantation
Conditions Studied
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL sargramostim
- BIOLOGICAL monoclonal antibody Ch14.18
- DRUG isotretinoin
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2001-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005576
The ClinicalTrials.gov registry entry for NCT00005576 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,139-participant average among 9 other Recurrent Neuroblastoma trials with a reported enrollment target (99% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Neuroblastoma appearing as the primary indexed condition, and to 4 interventions - of which aldesleukin is the first listed.
NCT00005576 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00005576 about?
NCT00005576 is a clinical study titled "Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma". Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Interleukin-2 may stimulate a ...
What is the current status of trial NCT00005576?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2001-01.
What conditions does trial NCT00005576 study?
This clinical trial studies the following conditions: Recurrent Neuroblastoma, Regional Neuroblastoma, Disseminated Neuroblastoma.
What interventions are being tested in trial NCT00005576?
The interventions under investigation include: aldesleukin (BIOLOGICAL), sargramostim (BIOLOGICAL), monoclonal antibody Ch14.18 (BIOLOGICAL), isotretinoin (DRUG).
Who is sponsoring clinical trial NCT00005576?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00005576 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
RECRUITING · Phase 1
-
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
ACTIVE NOT RECRUITING · Phase 1
-
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
COMPLETED · Phase 1
-
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
ACTIVE NOT RECRUITING
-
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.